Submitted by merckcom3067 in business
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors Merck (NYSE: MRK), known as MSD outside of the United States and Cana…